78304-53-7

Usage

Derivative of indole

A compound based on the heterocyclic compound indole

Phenyl group attachment

A phenyl group is attached to the 5 position of the indole derivative

Use in pharmaceutical research

Used as a building block for synthesizing organic molecules with potential pharmacological activities

Use as a starting material

Can be used to synthesize various compounds, including potential drug candidates

Unique structure and reactivity

Its structure and reactivity make it a valuable tool for medicinal chemistry and drug discovery efforts.

Upstream product

• 78304-48-0 ethyl pyruvate 4,4'-diphenyloxydihydrazone 
• 5762-56-1 tris(dimethylamino)methane 
• 112880-83-8 5-phenoxy-2-nitrotoluene 
• 108-95-2 phenol 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 57623-12-8 4,4'-dihydrazinodiphenyl oxide dihydrochloride 
• 6040-86-4 4,4'-diaminodiphenyl oxide dihydrochloride 
• 78304-51-5 ethyl 5-phenoxy-1H-indole-2-carboxylate 
• 446-33-3 5-Fluoro-2-nitrotoluene 
• 2581-34-2 3-methyl-4-nitrophenol 
• 930790-07-1 dimethyl-[2-(2-nitro-5-phenoxy-phenyl)-vinyl]-amine 
• 157060-89-4 trans-1-<2-(N,N-dimethylamino)ethenyl>-5-phenoxy-2-nitrobenzene 
• 78304-52-6 5-phenoxy-2-carboxyindole 

Downstream Products

• 157060-91-8 1,4-dimethyl-6-phenoxycarbazole 
• 163258-01-3 3-(1-methyl-1,2,5,6-tetrahydropyrid-4-yl)-5-phenoxyindole 
• 882803-34-1 5-phenoxy-1H-indazole-3-carbaldehyde 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

The present invention relates to chemical entities (for example, a pharmaceutically acceptable compound or salt, and / or a hydrate, and / or a co-crystal, and / or a combination of drug of the compound) which inhibit (for example, antagonize) the stimula

N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR

The present invention relates to the use compounds of formula I which are antagonists of the 5-HT 6 receptor, for treating a cognitive disorder selected from the group consisting of age-related cognitive decline, mild cognitive impairment and dementia

Phenylaminopropanol derivatives and methods of their use

The present invention is directed to phenylaminopropanol derivatives of formulae I, II, and III: [image] or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof.

3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors

The 3-benzimidazol-2-yl-1H-indazole scaffold was developed as an alternate scaffold for our receptor tyrosine kinase (RTK) inhibitor program. In exploring the SAR of this series, it was discovered that a subset of these compounds potently inhibit the enzy

Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications

Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective 3-[(benzothiazol-2-yl)methyl]indole-N-alkanoic acid aldose reductase inhibitors. The lead candidate, 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat, 9) inhibits aldose reductase with an IC50 of 5 nM, while being 5400 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes. It lowers nerve and lens sorbitol levels with ED50's of 1.9 and 4.5 mg/kg/d po, respectively, in the 5-day STZ-induced diabetic rat model. In a 3-month diabetic intervention model (1 month of diabetes followed by 2 months of drug treatment at 5 mg/kg/d po), it normalizes polyols and reduces the motor nerve conduction velocity deficit by 59% relative to diabetic controls. It has a favorable pharmacokinetic profile (F, 82%; t1/2, 5.6 h; Vd, 0.694 L/kg) with good drug penetration in target tissues (Cmax in sciatic nerve and eye are 2.36 and 1.45 μg equiv/g, respectively, when dosed with [14C] lidorestat at 10 mg/kg po).

Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids

Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds use

Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds use

Methods for reducing uric acid levels

Disclosed are methods of reducing serum uric acid levels, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds useful in the treatment of gout and related diseas

Substituted indolealkanoic acids

Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as we

Tryptamine analogues as 5-ht1-like agonists

A compound of structure (I), in which A1 is O, S(O)n in which n is 0, 1 or 2, NR, CH2, or CH(OH); A2 is a bond or CH2 ; or A1 A2 is CH=CH; R is hydrogen or C1-4 alkyl;